Table II. Baseline characteristics of all 885 first visits of offspring of women with PCOS and controls in this IPD analysis.
| Sir-Peterman et al. – Chilean data |
Legro et al. – USA data |
De Wilde et al. – Dutch data |
||||
|---|---|---|---|---|---|---|
| n = 288 | n = 225 | n = 372 | ||||
| PCOS | Controls | PCOS | Controls | PCOS | Controls | |
| n = 119 | n = 169 | n = 105 | n = 120 | n = 74 | n = 298 | |
| Baseline at birth | ||||||
| Sex (% girls) | 70 (59) | 80 (47) | 90 (86) | 103 (86) | 36 (48.6) | 171 (57.4) |
| Gestational age (weeks), median (IQR) | 39.0 (38.0–40.0) | 39.0 (38.0–40.0) | 40.0 (39.0–40.0) | 40.0 (40.0–40.0) | 39.1 (38.2–40.4) | 39.6 (39.0–40.6) |
| Birthweight (grams), mean (±) | 3287 ± 589 | 3323 ± 515 | 3726 ± 637 | 3806 ± 637 | 3304 ± 648 | 3569 ± 488 |
| Multiple gestation (%) | 0 (0%) | 0 (0%) | 2 twin pairs (1%) | 1 twin pair (2%) | 2 twin pairs (5%) | 4 twin pairs (3%) |
| Screening during childhood | ||||||
| Age at screening (year), mean (±) | 9.1 ± 3.6 | 10.4 ± 3.1 | 9.2 ± 3.5 | 10.2 ± 3.6 | 4.9 ± 2.0 | 5.6 ± 2.2 |
| BMI (kg/m2), median (IQR) | 19.3 (16.7–22.4) | 20.1 (17.4–22.8) | 19.8 (15.8–22.4) | 19.6 (16.1–21.9) | 15.6 ± 1.6 | 16.1 ± 1.5 |
| Waist (cm), median (IQR) | 62 (56–72) | 66 (60–73) | 62 (55–74) | 66 (56–75) | 52 (50–55) | 55 (52–58) |
| Waist to height ratio, mean (±) | 0.49 ± 0.1 | 0.47 ± 0.1 | 0.48 ± 0.1 | 0.47 ± 0.1 | 0.48 ± 0.1 | 0.48 ± 0.1 |
| SBP (mm Hg), mean (±) | 91 ± 11 | 93 ± 13 | 106 ± 14 | 107 ± 11 | 98 ± 8 | 99 ± 9 |
| DBP (mm Hg), mean (±) | 56 ± 9 | 57 ± 10 | 65 ± 8 | 65 ± 8 | 51 ± 7 | 52 ± 6 |
| Fasting glucose (mg/dL), mean (±) | 83 ± 10 | 83 ± 9 | 78 ± 10 | 78 ± 12 | 84 ± 6 | 82 ± 11 |
| Fasting 2-hour glucose (mg/dL), mean (±) |
99 ± 24 | 95 ± 17 | 86 ± 20 | 82 ± 17 | NA | NA |
| Fasting insulin (μU/ml), median (IQR) | 8 (5–14) | 10 (6–14) | 15 (6–21) | 13 (7–15) | 4 (2–5) | 5 (4–7) |
| Fasting 2-hour insulin (μU/ml), median (IQR) | 33 (13–63) | 32 (18–51) | 52 (31–86) | 49 (28–67) | NA | NA |
| HOMA-IR, median (IQR), median (IQR) | 2.3 (1.1–2.8) | 2.0 (1.2–2.8) | 3.3 (1.2–4.1) | 2.5 (1.3–2.0) | 0.9 (0.5–1.2) | 1.1 (0.7–1.4) |
| LDL-cholesterol (mg/dL), mean (±) | 93 ± 31 | 90 ± 35 | 58 ± 25 | 55 ± 21 | 120 ± 48 | 106 ± 24 |
| Total cholesterol (mg/dL), mean (±) | 157 ± 30 | 167 ± 31 | 150 ± 29 | 145 ± 12 | 189 ± 51 | 170 ± 27 |
| HDL-cholesterol (mg/dL), mean (±) | 44 ± 13 | 42 ± 10 | 84 ± 53 | 69 ± 32 | 56 ± 12 | 56 ± 10 |
| Triglycerides (mg/dL), mean (±) | 114 ± 45 | 116 ± 36 | 85 ± 27 | 82 ± 30 | 62 ± 21 | 42 ± 18 |
| Metabolic sum score-1 (SDS), mean (±) | 1.5 ± 2.9 | 1.0 ± 2.7 | 0.5 ± 4.0 | 1.6 ± 2.2 | −0.9 ± 1.2 | −1.3 ± 2.0 |
| Metabolic sum score-2 (SDS), mean (±) | 0.2 ± 2.6 | 0.1 ± 2.4 | −1.4 ± 4.3 | −0.3 ± 1.9 | −0.9 ± 1.1 | −1.6 ± 1.8 |
| Tanner stage: pubic hair | NA | NA | 1 (1–2) | 1 (1–3) | NA | NA |
| Tanner stage: breasts | 2 (1–4) | 2 (1–4) | 1 (1–3) | 1 (1–4) | NA | NA |
| Tanner stage: testis | 2 (1–3) | 2 (1–4) | 2 (0–4) | 1 (0–2) | NA | NA |
| Maternal age during screening child (years), mean (±) | 34.6 ± 7.2 | 37.9 ± 6.8 | 35.6 ± 5.8 | NA | 37.0 ± 4.4 | 38.2 ± 4.6 |
PCOS: polycystic ovary syndrome, SBP/DBP = systolic/diastolic blood pressure, NA = not available data, SDS = standardized deviation score, WHO = World Health Organization. Baseline characteristics in: n (%), mean (±: SD) or median with interquartile range (IQR): 25–75th percentile.